Drug Profile
FM 101 - Future Medicine
Alternative Names: FM-101-Future MedicineLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Future Medicine
- Class Eye disorder therapies; Hepatoprotectants; Nucleosides; Small molecules
- Mechanism of Action Adenosine A3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Phase I/II Glaucoma; Ocular hypertension
- Phase I Diabetic neuropathies; Primary biliary cirrhosis
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Glaucoma(In volunteers) in Netherlands (PO, Tablet)
- 14 Jan 2021 Future Medicine plans a phase II trial for Nonalcoholic fatty liver disease or Nonalcoholic steatohepatitis in April 2021 (NCT04710524)
- 07 Oct 2020 Phase-I/II clinical trials in Ocular hypertension (In adults, In the elderly, In volunteers) in Australia (PO, Liquid) (NCT04585100)